Presentations

2cureX at Redeye Life Science Day 2020


2cureX: Ole Thastrup and Maarten van der Linden presents at Redeye Life Science Day 2020, 26th November 2020, Stockholm.

2cureX at Life Science Økonomisk Ugebrev


Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) present at Life Science Økonomisk Ugebrev, 25th November 2020, Copenhagen.

2cureX at Danish Shareholders’ Association (Investor-Ugen)


Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) give latest 2cureX outlook (2021-2023) at Danish Shareholders’ Association (Investor-Ugen), Copenhagen, November 12, 2020.
Download accompanying presentation

Benefits of IndiTreat® Sensitivity Test


Dr. Henrik Harling (2cureX CMO) discussing the dilemma facing the oncologist on the choice of first line colorectal cancer treatment.
Download accompanying presentation

IndiTreat® Sensitivity Test availability


Maarten van der Linden (2cureX CBO) talking about availability and application of IndiTreat® Sensitivity Test for colorectal, pancreatic and ovarian cancer patients.
Download accompanying presentation

2cureX presentation for investors


Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) present 2cureX at Sedermeradagen in Copenhagen on March 11, 2020.

2cureX presentation for investors


Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) present 2cureX at Sedermeradagen in Copenhagen, 2019.

Upcoming events

January 21, 2021

Fight Cancer 2021, Redeye Event, Stockholm

Click here for more information

February 10, 2021

VATOR SWISS NORDIC BIO 2021 – The Annual Nordic Healthcare Investor Summit in Zürich

Read more

February 25, 2021

2cureX Year-End Report 2020

View previous reports

IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.